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Longitudinal analyses of the DNA methylome in deployed
military servicemen identify susceptibility loci for
post-traumatic stress disorder
BPF Rutten1, E Vermetten2,3,4, CH Vinkers2,17, G Ursini5,17, NP Daskalakis6,17, E Pishva1, L de Nijs1, LC Houtepen2, L Eijssen1, AE Jaffe5,
G Kenis1, W Viechtbauer1, D van den Hove1,7, KG Schraut7, K-P Lesch1,7, JE Kleinman5, TM Hyde5, DR Weinberger5,8,9,10, L Schalkwyk11,
K Lunnon12, J Mill12, H Cohen13, R Yehuda6, DG Baker14,15,16, AX Maihofer14,15,16, CM Nievergelt14,15,16, E Geuze2,3 and MPM Boks2
In order to determine the impact of the epigenetic response to traumatic stress on post-traumatic stress disorder (PTSD), this study
examined longitudinal changes of genome-wide blood DNA methylation proﬁles in relation to the development of PTSD symptoms
in two prospective military cohorts (one discovery and one replication data set). In the ﬁrst cohort consisting of male Dutch military
servicemen (n= 93), the emergence of PTSD symptoms over a deployment period to a combat zone was signiﬁcantly associated
with alterations in DNA methylation levels at 17 genomic positions and 12 genomic regions. Evidence for mediation of the relation
between combat trauma and PTSD symptoms by longitudinal changes in DNA methylation was observed at several positions and
regions. Bioinformatic analyses of the reported associations identiﬁed signiﬁcant enrichment in several pathways relevant for
symptoms of PTSD. Targeted analyses of the signiﬁcant ﬁndings from the discovery sample in an independent prospective cohort
of male US marines (n= 98) replicated the observed relation between decreases in DNA methylation levels and PTSD symptoms at
genomic regions in ZFP57, RNF39 and HIST1H2APS2. Together, our study pinpoints three novel genomic regions where longitudinal
decreases in DNA methylation across the period of exposure to combat trauma marks susceptibility for PTSD.
Molecular Psychiatry (2018) 23, 1145–1156; doi:10.1038/mp.2017.120; published online 20 June 2017
INTRODUCTION
Exposure to extreme psychological stress such as is experienced
during combat situations can result in the development of post-
traumatic stress disorder (PTSD).1 Mounting evidence from recent
cross-sectional human and animal studies suggests that epige-
netic mechanisms, particularly DNA methylation, may play a key
role in adaptation to traumatic stress.2–5 Human studies on the
effect of traumatic stress have been constrained by the limited
accessibility of the primary tissue type of interest (i.e., the human
brain)6 and by difﬁculties in prospectively capturing the effects of
robust and relevant trauma exposures. To investigate the role of
DNA methylation following traumatic stress, and its putative role
in the development of PTSD, it is useful to focus on longitudinal
studies that are less burdened by potential confounders, not the
least genetic background. Here, for we believe the ﬁrst time, a
prospective study design in military service members deployed to
a combat zone in Afghanistan was used in order to discover
differentially methylated positions (DMPs) and differentially
methylated regions (DMRs), where longitudinal changes in blood
DNA methylation proﬁles were signiﬁcantly associated with the
development of PTSD. Findings from this methylome discovery
study were replicated in an independent prospective military
cohort, and were technically validated. Figure 1a and Table 1A
illustrate the overall study design.
MATERIALS AND METHODS
The overall study design is illustrated in Figure 1a. The study consisted of
two different data sets (see Table 1A). The subjects and the methods used
for the data sets are indicated below.
Discovery data set
All subjects in the discovery data set were male participants in PRISMO, a
large prospective study of 1032 well-characterized Dutch military soldiers
scheduled for a deployment of at least 4 months to Afghanistan with
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longitudinal follow-up.7,8 This study used data obtained 1 month before
and 6 months after the deployment period.
Subject selection. A subset (total n=93) of three similarly sized subgroups
of study participants was pre-selected (see also Table 1B) based on the
level of traumatic stress exposure and the presence of PTSD symptoms: (i)
a subgroup showing high combat-trauma exposure (7.3 ± 2.9) on the
deployment experiences checklist, and high levels of post-deployment
PTSD symptoms (45.3 ± 8.6) Self-Report Inventory for PTSD; (ii) a subgroup
showing high combat-trauma exposure (8.6 ± 2.3) and a low severity
of PTSD symptoms (26.0±3.7); and (iii) a subgroup showing low combat-
trauma exposure (0.4 ± 0.5) and low levels of post-deployment PTSD
symptoms (25.1 ± 3.7). Analysis of age, gender, alcohol consumption,
cigarette smoking, military rank, height, weight and medication use did
not show any differences among these three groups, although reported
exposure to childhood trauma was signiﬁcantly higher in the group of
soldiers who developed symptoms of PTSD after combat trauma (see
Table 1B).
Figure 1. (a) Overall study design. Schematic illustration of the overall study design. Discovery of 17 differentially methylated positions (DMPs)
and 12 differentially methylated regions (DMRs) through genome-wide analyses of longitudinal changes in blood-based DNA methylation
proﬁles of military soldiers in relation to the development of psychopathology after deployment to a combat zone was followed by statistical
mediation and bioinformatics analyses. Next, these 17 DMPs and 12 DMRs were investigated for replication in an independent prospective
military cohort. (b) Manhattan plot of results of PTSD-related differential methylation in the discovery data set. Manhattan plot of the P-values
for the regression analyses of longitudinal changes in methylation as a function of changes in PTSD scores in soldiers exposed to traumatic
stress during deployment in the discovery data set. Red vertical lines indicate the locations of DMRs. PTSD, post-traumatic stress disorder.
Changes in DNA methylation during development of PTSD
BPF Rutten et al
1146
Molecular Psychiatry (2018), 1145 – 1156
Blood samples were collected before and 6 months after deployment.
The blood cell-type composition was investigated using ﬂow cytometry,
implemented in the clinical laboratory of Utrecht University Medical
Center, as previously reported.9 The presence and severity of symptoms of
PTSD over the previous 4 weeks were assessed with the 22-item Self-
Report Inventory for PTSD (SRIP), which has good reliability and validity.
Differences in PTSD symptoms between time points were log-transformed
to improve the distribution. Exposure to traumatic stress during deployment
was assessed with a 19-item deployment experiences checklist, as previously
reported.10 This self-report assessment covered a range of potentially
traumatic experiences that occur during deployment, including direct
combat stressors. Childhood trauma was assessed with the 27-item Dutch
version of the self-reporting short-form Early Trauma Inventory (ETISR-SF),11
assessing early traumatic experiences before the age of 18 years, including
general trauma, physical abuse, emotional abuse and sexual abuse.
Differences in PTSD symptom scores between time points were log-
transformed to improve the distribution. Three missing values in the baseline
measure of PTSD symptoms were replaced with the median. General mental
health symptoms were also assessed with the Dutch revised version of the
Symptom Checklist (SCL-90-R). The SCL-90-R consists of 90 items measuring
general mental health, is frequently used in clinical samples and shows good
reliability. This study was approved by the ethical committee of University
Medical Center Utrecht (01-333/0) and conducted in accordance with the
Declaration of Helsinki. All participants gave written informed consent.
Methylome analysis. Genome-wide DNA methylation was assessed using
the Illumina Human methylation 450 BeadChip (Illumina, San Diego, CA,
USA), which interrogates4485 000 methylation sites per sample at single-
nucleotide resolution. Bisulphite-converted DNA was subjected to whole-
genome ampliﬁcation, followed by fragmentation and hybridization of
probes. Baseline and follow-up samples were positioned on the same
array, and exposure to trauma and PTSD outcomes was equally distributed
over the 16 arrays to minimize potential batch effects. Background
corrected signal intensities for each probe were extracted using Illumina
GenomeStudio software and imported into R. Comparison of non-CpG SNP
probes on the array conﬁrmed that two samples per individual were plated
on the same array. Probes containing an single-nucleotide polymorphism
(SNP) with a minor allele frequency 45% within 10 bp of the single-base
extension site according to Illumina’s database were removed from all
analyses. Further data quality control and processing steps were
conducted using the wateRmelon and SVA packages in R. No sample
exhibited 5% of sites with a detection P-value greater than 0.001. A total of
490 sites were removed with beadcount o3 in 5% of samples, and 9728
sites showing 1% of samples with a detection P-value greater than 0.001
were also removed. X-chromosome, Y-chromosome and cross-hybridizing
probes probe sequences were also removed.12
Longitudinal changes in DNA methylation per subject were analysed for
39 560 CpG loci. The combat procedure from the SVA package was used to
remove plate, sentrix and position effects from the data (Supplementary
Figure S1 shows the batch effects before and after removal).
To identify DMPs, longitudinal analyses were conducted using DNA
methylation at 6 months after deployment as the outcome via linear
regression with DNA methylation levels at 1 month before deployment as
a covariate; that is, methylationpostdeployment ~ methylation pre-deploy-
ment+change in PTSD symptoms. The qq plot of the expected P-values
versus the observed P-values and a lambda of 0.998 (see Supplementary
Figure S2) indicated absence of type-I error inﬂation and no artiﬁcial
differences between groups. False discovery rate (FDR) P-values were
calculated according to the Benjamini–Hochberg method. Label-swapping
permutations with 100 000 random permuted outcomes were used to
derive empirical P-values. The assumptions of the linear regression were
evaluated by inspecting the distribution of residuals for the identiﬁed loci.
The cell-type composition before and after deployment was obtained on the
basis of FACS cell counts, as previously described,9 and compared using
repeated-measures analysis of variance as well as added to the longitudinal
model. The potential inﬂuences of cigarette smoking, alcohol use and
medication were investigated by excluding participants with documented
changes in these parameters from the analysis (N=17, N=5 and N=15,
respectively). Gaps in the distribution of the DNA methylation levels were
detected with ‘gaphunter, see (http://ﬁnzi.psych.upenn.edu/library/minﬁ/
html/gaphunter.html) using a threshold of 0.075 and cutoff value of 0.1.
Multilevel analysis, including the band number as random effect, was
performed in order to test the potential effect of banding on the
associations between longitudinal change in DNA methylation and long-
itudinal change in PTSD symptoms. For probes showing effects of banding
on the longitudinal changes, stratiﬁed analyses per band were performed.
To identify DMRs, we used a script that calculated regional P-values
using a sliding-window algorithm, as implemented in comb-p code in
Python.13 DMRs were deﬁned as three or more adjacent CpG sites on the
arrays showing Po0.05. Correction for multiple testing in DMRs was
performed using the Šídák FDR at the 0.05% level.
Table 1B. Demographics and clinical characteristics of the discovery data set
All (N= 93) Group 1 (N=32) Group 2 (N=29) Group 3 (N= 32)
Post-deployment PTSD symptoms High Low Low
Combat trauma exposure High High Low
Race (% European Caucasian) 100 100 100 100
Age (s.d.) 27.5 (9.1) 26.8 (9.6) 27.7 (9.1) 28.1 (8.8)
Mean trauma score (s.d.) 5.3 (4.2) 7.3 (2.9) 8.6 (2.3) 0.4 (0.5)
PTSD pre-deployment 26.4 (3.9) 27.9 (4.1) 26.0 (3.8) 25.4 (3.4)
PTSD symptoms at follow-up (s.d.) 32.4 (11.1) 45.3 (8.6) 26.0 (3.7) 25.1 (3.7)
Change in PTSD symptoms (s.d.) 5.9 (10.8) 17.4 (10.1) 0.0 (3.6) − 0.3 (4.8)
Height 1.83 (0.06) 1.83 (0.06) 1.82 (0.06) 1.82 (0.07)
Weight 82.6 (11.5) 84.5 (8.6) 82.5 (10.7) 80.9 (14.2)
Change in SCL-90 score 6.6 (21.8) 20.4 (31.0) 0.8 (11.5) 0.7 (10.1)
Childhood trauma score 3.1 (2.7) 4.8 (3.1) 3.2 (2.3) 1.3 (1.1)
Number of deployments 0.9 (1.2) 0.8 (1.2) 1.2 (1.4) 0.6 (0.8)
Time to follow-up (months) (s.d.) 13.5 (3.7) 13.4 (3.8) 13.5 (3.2) 13.4 (3.7)
Abbreviations: PTSD, post-traumatic stress disorder; SCL-90, Symptom Check List—90-item questionnaire; s.d., standard deviation.
Table 1A. Data sets used in this study
Data set Discovery Replication
Name PRISMO cohort Marine Resiliency
Study
Study design Longitudinal Longitudinal
Sample 93 humans 98 humans
Sex Male Male
Traumatic stress
exposure
Combat trauma Combat trauma
Phenotype PTSD symptoms PTSD symptoms
SCL-90
Tissue source Blood Blood
Methylation data 450 K BeadChip
array
450 K BeadChip array
Abbreviations: PTSD, post-traumatic stress disorder; SCL-90, Symptom
Check List--90-item questionnaire.
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Table 2A. List of genome-wide signiﬁcant differentially methylated positions (DMPs)
Gene Probe Chrom Genomic characteristics β P-value FDR Permuted Number
of bands
Banding
adjusted
Mediation % Replication
P-value P-value P-value PTSD (CI) β P-value
DUSP22 cg03395511 6 TSS200 N_Shore Promoter − 0.082 2.34 E-07 0.01024 o1.00 E-5 2 6.74 E-05 NS 0.44 0.005
DUSP22 cg18110333 6 1stExon;5'UTR Island Promoter − 0.166 6.89 E-09 0.00092 o1.00 E-5 2 4.31 E-05 NS 0.59 0.016
DUSP22 cg21548813 6 TSS1500 N_Shore Promoter − 0.099 1.40 E-08 0.00092 o1.00 E-5 2 5.99 E-05 NS 0.38 0.028
DUSP22 cg01516881 6 Body Island Promoter − 0.074 4.52E-07 0.01483 o1.00 E-5 2 1.54 E-05 NS 0.21 0.027
DUSP22 cg11235426 6 1stExon;5'UTR Island Promoter − 0.077 6.65 E-07 0.01871 o1.00 E-5 2 1.37 E-07 NS 0.21 40.05
NINJ2 cg14911689 12 Body Promoter − 0.134 8.61 E-09 0.00092 o1.00 E-5 2 1.74 E-08 NS − 0.14 40.05
NINJ2 cg26654770 12 Body Promoter − 0.1 6.10 E-07 0.01847 o1.00 E-5 2 3.23 E-06 NS − 0.24 40.05
HOOK2 cg06417478 19 Body N_Shore Unclassiﬁed − 0.145 2.88 E-10 0.00011 o1.00 E-5 2 7.83 E-07 − 0.62%
(−0.11 to − 0.07)
0.41 40.05
HOOK2 cg11738485 19 Body Island Unclassiﬁed − 0.181 1.29 E-08 0.00092 o1.00 E-5 4 5.63 E-03 − 0.67%
(−0.13 to − 0.08)
0.11 4 0.05
HOOK2 cg04657146 19 Body Island Unclassiﬁed − 0.111 3.45 E-08 0.00194 o1.00 E-5 3 1.40 E-01 − 0.44%
(−0.09 to − 0.05)
0.26 4 0.05
SDK1 cg07249765 7 Body − 0.093 5.41 E-08 0.00266 o1.00 E-5 2 1.20 E-07 NS 0.50 0.017
MYT1L cg10075506 2 Body − 0.113 1.28 E-06 0.03163 o1.00 E-5 1 2.18 E-06 − 0.67%
(−0.13 to − 0.09)
− 0.17 4 0.05
PAX8 cg11763394 2 Body; TSS1500 N_Shore Unclassiﬁed − 0.092 1.29 E-06 0.03163 o1.00 E-5 1 5.87 E-06 NS − 0.10 4 0.05
COL1A2 cg24406898 7 TSS1500 − 0.085 1.79 E-06 0.04162 o1.00 E-5 1 6.91 E-08 NS 0.04 4 0.05
cg22676075 6 Unclassiﬁed − 0.101 1.29 E-08 0.00092 o1.00 E-5 1 1.77 E-08 NS 0.11 4 0.05
HIST1H2APS2 cg03517284 6 S_Shore Unclassiﬁed − 0.085 3.51 E-07 0.01271 o1.00 E-5 1 2.44 E-06 NS − 0.15 0.002
cg05785424 17 Promoter − 0.118 3.55 E-07 0.01271 o1.00 E-5 2 1.71 E-06 NS 0.08 4 0.05
Mediating
DMPs together
− 1.26%
(−0.24 to − 0.18)
Abbreviations: Chrom, chromosome; COL1A2, Collagen Type I; DUSP22, Dual-Speciﬁcity Phosphatase 22; FDR, false discovery rate using the Bonferroni post hoc test corrected P-value; Gene, gene symbol;
HIST1H2APS2, Alpha 2, Histone cluster 1 H2a pseudogene 2; HOOK2, Hook microtubule-tethering protein 2; MYT1L, Myelin Transcription Factor 1-Like; NINJ2, Ninjurin (Nerve Injury-Induced Protein) 2; NS,
nonsigniﬁcant; PAX8, Paired box 8; PSTD, post-traumatic stress disorder; SCL-90, Symptom Checklist, 90 items; SDK1, Sidekick Cell Adhesion Molecule 1. The percentage mediation reﬂects the percentage of
variance in the association between traumatic stress exposure and changes in PTSD scores explained by the change in DNA methylation of the corresponding probe. These percentages are provided only for
DMPs showing statistical evidence of mediation. The last row relates to the results on mediation of the (statistically signiﬁcant) mediating DMPs analysed in conjunction, that is, in one analysis. The number of
bands refers to the results of testing gaps and bands in the distributions of the DNA methylation levels. Banding corrected P-values refer to the statistical signiﬁcance on the change in DNA methylation in
relation to change in symptoms of PTSD as tested by multilevel analysis (i.e. within bands). The column with the results of the mediation analyses provides the percentage of difference in the coefﬁcient
between the two models tested as well as the conﬁdence interval from bootstrapping (only for the loci showing signiﬁcant mediation). The column on replication provides the β and P-values for the regression
analyses on the change in DNA methylation in relation to change in symptoms of PTSD in the MRS cohort.
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Table 2B. List of genome-wide signiﬁcant differentially methylated regions (DMRs)
Chromosomal position of DMR Genes with
nearby TSS
Probes Genomic characteristics Permutation
P-value
Minimum
P-value
Overall
P-value
Šídák
corrected
P-value
Number
of bands
Banding-
adjusted
P-value
Mediation
%
(conﬁdence
interval)
P-value in
replication
data set
DMR1 chr19:12876845,
12877189
HOOK2
(+9417),
BEST2
(+13610)
cg06417478 Body N_Shore Unclassiﬁed o1.00 E-5 6.49 E-15 6.60 E-20 1.69 E-14 4 3.58
E-02
− 0.57%
(−0.11 to
− 0.07)
40.05
cg04657146 Body Island Unclassiﬁed
cg11738485 Body Island Unclassiﬁed
cg23899408 Body S_Shore Unclassiﬁed
DMR2 chr6:291686,
291910
DUSP22
(−303)
cg07332563 TSS1500 N_Shore Promoter o1.00 E-5 7.15 E-13 1.45 E-17 5.72 E-12 2 9.35
E-06
NS 40.05
cg21548813 TSS1500 N_Shore Promoter
cg03395511 TSS200 N_Shore Promoter
cg15383120 TSS200 N_Shore Promoter
DMR3 chr6:292328,
292597
DUSP22
(+362)
cg18110333 1stExon;5'UTR Island Promoter o1.00 E-5 4.71 E-10 1.44 E-14 4.71 E-9 2 9.94
E-07
40.05
cg05064044 1stExon;5'UTR Island Promoter
cg11235426 1stExon;5'UTR Island Promoter
cg01516881 Body Island Promoter
DMR4 chr12:739979,
740339
NINJ2
(+32596),
B4GALNT3
(+170616)
cg26371957 Body Promoter o1.00 E-5 3.65 E-12 1.91 E-16 5.44 E-8 1 5.19
E-07
NS 40.05
cg14911689 Body Promoter
cg26654770 Body Promoter
DMR5 chr2:113992761,
113993143
PAX8
(+43546),
PSD4
(+61392)
cg21482265 Body;TSS1500 N_Shore Unclassiﬁed 1.00 E-5 2.02E-9 1.02E-15 2.31 E-7 1 8.81
E-06
0.26%
(−0.06 to
− 0.03)
40.05
cg12889195 Body;TSS1500 N_Shore Unclassiﬁed
cg11763394 Body;TSS1500 N_Shore Unclassiﬁed
cg21550016 Body;TSS1500 N_Shore Unclassiﬁed
cg07772999 Body;TSS1500 N_Shore Unclassiﬁed
cg19083407 Body;TSS1500 N_Shore Unclassiﬁed
DMR6 chr21:47604653,
47605175
SPATC1L
(−541)
cg05896524 TSS1500 S_Shore Unclassiﬁed o1.00 E-5 8.24 E-8 6.22 E-12 1.05 E-9 1 6.06
E-06
− 0.84%
(−0.17 to
− 0.09)
40.05
cg13012494 TSS1500 S_Shelf Unclassiﬁed
cg13732083 TSS1500 S_Shelf Unclassiﬁed
cg10296238 TSS1500 S_Shelf Unclassiﬁed
DMR7 chr1: 205819087,
205819493
PM20D1
(−14)
cg26354017 1stExon Island Unclassiﬁed 0.00135 5.88 E-07 2.80 E-9 6.08 E-4 1 9.99
E-04
− 0.63%
(−0.13 to
− 0.07)
40.05
cg14159672 1stExon Island Unclassiﬁed
cg14893161 5'UTR;1stExon S_Shore Unclassiﬁed
cg11965913 TSS200 S_Shore Unclassiﬁed
cg07167872 TSS200 S_Shore Unclassiﬁed
cg24503407 TSS1500 S_Shore Unclassiﬁed
DMR8 chr15:66947391
66947618
LCTL
(−89670),
SMAD6
(−47169)
cg09827761 Island Unclassiﬁed o1.00 E-5 4.80 E-4 3.53 E-8 1.37 E-2 1 1.55
E-07
NS 40.05
cg25481157 Island Unclassiﬁed
cg26099834 Island Unclassiﬁed
cg05406088 S_Shore
DMR9 chr5:135416204,
135416614
SMAD5
(−52127),
cg04481923 Body Island Unclassiﬁed 0.01663 1.52E-6 1.46 E-7 3.15 E-2 3 1.95
E-02
0.15%
(−0.04 to
− 0.01)
40.05
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Table 2B. (Continued )
Chromosomal position of DMR Genes with
nearby TSS
Probes Genomic characteristics Permutation
P-value
Minimum
P-value
Overall
P-value
Šídák
corrected
P-value
Number
of bands
Banding-
adjusted
P-value
Mediation
%
(conﬁdence
interval)
P-value in
replication
data set
TGFBI
(+51825)
cg18678645 TSS200 Island Unclassiﬁed
cg06536614 TSS200 Island Unclassiﬁed
cg26328633 TSS200 Island Unclassiﬁed
cg25340688 TSS200 Island Unclassiﬁed
cg26896946 TSS200 Island Unclassiﬁed
cg00124993 TSS200 Island Unclassiﬁed
cg08745965 TSS1500 S_Shore Unclassiﬁed
cg16615357 TSS1500 S_Shore Unclassiﬁed
cg18797653 TSS1500 S_Shore Unclassiﬁed
DMR 10 chr6:29648524,
29648757
ZFP57
(−3710)
cg20228636 Unclassiﬁed 0.00127 0.009283 3.12 E-6 0.001181 2 6.05
E-04
NS 1.32E-14
cg27414868 Unclassiﬁed
cg11383134 Unclassiﬁed
cg03198009 Unclassiﬁed
DMR 11 chr13:27295927,
27296011
GPR12
(+38953),
WASF3
(+164129)
cg01903420 Unclassiﬁed o1.00 E-5 1.11 E-02 1.38 E-6 0.001452 2 1.01
E-07
− 0.03%
(−0.01 to
− 0.003)
40.05
cg16557370 Unclassiﬁed
cg08419873 Unclassiﬁed
DMR 12 chr6:30039402,
30039467
RNF39
(+4193),
PPP1R11
(+4503)
cg09279736 Body Island 0.00024 0.02133 2.02E-9 0.002737 1 2.06
E-04
− 0.62%
(−0.11 to
− 0.08)
0.0026
cg13401893 Body Island
cg12633154 Body Island
cg10568066 Body Island
cg16078649 Body Island
Mediating
DMRs together
− 2.1%
(−0.04 to
−0.26)
Abbreviation: NS, nonsigniﬁcant. The percentage mediation reﬂects the percentage of variance of the association between traumatic stress exposure and changes in PTSD scores explained by the change in
DNA methylation of the corresponding probes. These percentages (and the respective conﬁdence intervals) were provided only for DMRs showing statistical evidence of mediation. The last row relates to the
results on mediation of the (statistically signiﬁcant) mediating DMRs analysed in conjunction, that is, in one analysis. The number of bands refers to the results of testing gaps and bands in the distribution of the
DNA methylation levels. Banding corrected P-values reﬂect the signiﬁcance of a banding effect on the change in DNA methylation in relation to change in symptoms of PTSD as tested by multilevel analysis (i.e.
within bands). The column with the results of the mediation analyses provides the percentage of difference in the coefﬁcient between the two models tested as well as the conﬁdence interval from
bootstrapping (only for the regions showing signiﬁcant mediation). The column on replication provides the P-values for the analyses on the change in DNA methylation at the DMR in relation to change in
symptoms of PTSD in the MRS cohort.
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To statistically test for mediation, the standard Baron and Kenny method
was used to examine whether the changes in PTSD scores in traumatic
stress-exposed subjects are driven by the longitudinal changes in DNA
methylation levels at the DMPs and DMRs. First, the direct effect of trauma
stress exposure on PTSD scores were tested using multilevel regression
model with random intercepts (model 1), and in the second place, the
effect of both traumatic stress and DNA methylation were regressed on the
phenotype changes (model 2). Regression models were analysed with a
linear model ‘lme’ function of nlme package, and the percentage of
difference in the coefﬁcient obtained from model 1 and the coefﬁcient
obtained from model 2 was calculated. In order to examine whether the
difference is signiﬁcantly different from zero, bootstrapping was applied
using boot.ci function from the boot R package. The resulting bootstrap
distribution of the changes in the coefﬁcients was plotted and the bias
corrected and the accelerated bootstrap conﬁdence interval of the
distribution was computed. If zero was not included in the interval, then
this was taken as evidence of partial mediation by the methylation
changes. Statistical evidence of mediation was concluded if zero was not
included in the bootstrap conﬁdence interval, and the percentage of
mediation was calculated from the regression models. All statistical
analyses were performed using the R language for statistical computing
(R version 3.1.2).
Technical validation of the array-based DNA methylation quantiﬁcations
for the DMRs in ZP57 and RNF39 was performed using pyrosequencing
(EpigenDx, Hopkinton, MA, USA; using the Pyrosequencing PSQ96 HS
System, Pyrosequencing; Qiagen). RNF39 was measured by sequencing of
the region Chr6:30071666-30071627 using a single amplicon that included
cg03198009, cg11383134, cg27414868 and cg20228636 but not the CpG
cg16078649 that is directly adjacent, but is part of the original DMR. The
ZFP59 DMR was measured using two amplicons (Chr6:29680852-29680731)
that included all CpGs from the ZFP59 DMR (cg10568066, cg12633154,
cg13401893 and cg09279736). The average methylation level for the CpG
sites was calculated for the two DMRs as were parametric correlations with
the array-based data.
Bioinformatic analyses. The numbers of CpGs probes per gene were ﬁrst
corrected using a logistic modelling approach, based on an algorithm
previously published.14 Gene Ontology (GO) analysis was then performed
using GOrilla to identify overrepresented GO terms at the 0.05 Šídák-
adjusted level, based on genes showing changes in DNA methylation for
the Molecular Function, Cellular Component and Biological Process
ontologies. Pathway analysis was performed using PathVisio 3 with the
human WikiPathways analysis collection (downloaded 12 March 2015). To
map data points to pathway elements, the identiﬁer mapping database
Hs_Derby_20130701.bridge was used. Through overrepresentation analy-
sis, pathways that contained a higher than expected number of genes with
altered methylation were identiﬁed. In order to ﬁlter GO terms with
overlapping genes, an additional logistic model was run on all GO terms
containing 10 to 2000 genes and having a one-sided P-value of 0.05
(Z-score 1.645).
For the GO and pathway analyses, the most signiﬁcant CpG according to
GREAT annotation was selected for each gene, yielding a data set
containing 15 950 unique genes, among which 6774 mapped to at least
one pathway in the collection. Genes with a DMP showing an absolute
methylation change of at least 0.01 and a maximum Šidák corrected
P-value of 0.05 for their most signiﬁcant CpG island were considered as
signiﬁcantly changed.
Network analysis was performed based on the genes associated with the
DMRs. Genes near or consisting the DMRs (rather than the DMPs) were
used for the network analysis because DMRs reﬂect more robust genomic
alterations in DNA methylation than DMPs and because the DMR analysis
yielded an appropriate numbers of genes for performing network analyses.
An initial network was constructed by running GeneMania using the
default of adding 20 extra nodes based on a variety of sources. The
resulting network was imported into Cytoscape 3, which was used to lay
out the network and map the data (methylation changes and Šídák-
adjusted P-values) to the nodes.
Replication data set
Replication data were obtained from the Marine Resiliency Study, a
prospective PTSD study with longitudinal follow-up (pre- and post-
exposure to combat stress) of 2,599 US Marines bound for deployment
to Iraq/Afghanistan.15 Baseline measures were recorded approximately one
month pre-deployment. Follow-up was performed at approximately
1 week, 3 months and six months post-deployment. Post-traumatic stress
(PTS) symptoms were assessed using a structured diagnostic interview and
the Clinician Administered PTSD Scale (CAPS), and combat exposure was
assessed using the Deployment Risk and Resilience Inventory (DRRI).16 A
homogeneous subset of 98 men from the MRS was selected for DNA
methylation analyses. The mean combat exposure score using the DRRI for
these subjects was 0.77 (s.d. 0.62). The selected subjects showed no PTSD
diagnosis (CAPS⩽ 25) before deployment and reported relatively high
combat exposure during the index deployment. At six months post-
deployment, 35 cases were diagnosed with partial or full PTSD with a mean
CAPS score of 55.03 (standard deviation 16.05), and 63 controls showed no
PTSD symptoms at any time point (CAPS⩽ 25). The institutional review
boards of the University of California San Diego, VA San Diego Research
Service, and Naval Health Research Center approved the study. All subjects
provided informed consent.
Genome-wide DNA methylation levels were assessed in DNA extracted
from whole blood using the Inﬁnium HumanMethylation450 array.
Baseline and follow-up samples were positioned differently between
studies. Methylation level βs were calculated using the Minﬁ package and
normalized to correct for type-I and II probe design bias using the BMIQ
procedure implemented in watermelon. Batch and plate effects were
removed using COMBAT. Relative proportions of cell compositions were
estimated to account for cellular heterogeneity in blood-derived samples
using the Minﬁ package.17 Analyses were targeted at the DMPs and DMRs
identiﬁed in the discovery.
Relevance beyond PTSD. For the DMP and DMRs discovered in the Dutch
military cohort and subsequently replicated, we also explored whether
changes in DNA methylation levels were related to global expression of
symptoms of mental disorders; broader than PTSD. Global expression of
symptoms of mental disorders was assessed using the Symptom CheckList
90 (SCL-90) questionnaire at baseline and the 6 months follow-up within
the Dutch military cohort. Regressions analyses tested for associations
between longitudinal changes in DNA methylation and longitudinal
changes in SCL-90 scores.
RESULTS
Discovery of PTSD susceptibility in a Dutch military cohort: DMPs
After FDR adjustment at the 0.05 level, regression analyses
identiﬁed 17 genome-wide signiﬁcant CpG sites (DMPs) in/near
the genes DUSP22, NINJ2, HOOK2, PAX8, COL1A2, SDK1, MYT1L and
HIST1H2APS2, in which longitudinal changes in DNA methylation
were associated with increasing PTSD symptoms (Figure 1b and
Table 2A). The direction of effect for all identiﬁed DMPs was
negative, meaning that increases in PTSD symptoms were
associated with decreases in DNA methylation at those DMPs
over time.
To statistically test whether DNA methylation at the identiﬁed
CpG sites may be a causal mediator in the association between
traumatic stress exposure and longitudinal changes in PTSD
symptoms, bootstrapping analyses (N= 10 000) were performed in
the trauma-exposed subjects showing increased PTSD symptoms
over time. These analyses indicated that the strength of the
association between traumatic stress exposure and the long-
itudinal changes in PTSD symptom scores was co-dependent on
the methylation of three DMPs in HOOK2 and 1 DMP in MYT1L
(see Table 2A). The DNA methylation changes observed at the
DMPs accounted for a signiﬁcant but very small proportion of the
variance in the longitudinal changes in PTSD symptoms, that is,
the individual DMPs explained between 0.4 and 0.7% of the
variance (see Table 2A), while a conjunct analysis of the seven
genome-wide DMPs showing statistical mediation indicated that
these DMPs together explained 1.3% of the variance.
Discovery of PTSD susceptibility: DMRs
Twelve DMRs (see Table 2B) were identiﬁed, where longitudinal
changes in average DNA methylation were associated with
longitudinal changes in PTSD symptoms. These DMRs were
located in or near the transcription start sites of several genes.
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The direction of the association with PTSD symptoms was
negative for all loci in the DMRs, indicating that increased PTSD
symptom scores over time were associated with decreased DNA
methylation levels at the DMRs.
The strength of the observed associations between traumatic
stress and PTSD symptoms was mediated by DNA methylation
changes of seven DMRs in HOOK2, PAX8, SPATC1L, PM20D1,
SMAD5, GPR12 and RNF39 (see Table 2B) although mediation
accounted for a very small proportion (between 0.1 and 0.8%) of
the variance in changes in PTSD symptoms (see Table 2B).
The results of sensitivity analyses for the potential confounders
childhood trauma, age, actual time in weeks between baseline
and follow-up measurements, cell-type-composition, or changes
in smoking, medication and alcohol use indicated no signiﬁcant
effects of childhood trauma levels, age, actual time in weeks
between baseline and follow-up measurements, cell-type compo-
sition and change in use of alcohol or medication, while change in
smoking inﬂuenced the association between DNA methylation
changes of the DMR in SMAD5, but not for any other DMP or DMR.
Although probes containing an SNP with a minor allele
frequency 45% and located within 10 bp of the single-base
extension site according to Illumina’s database were removed in
the analysis pipeline, banding effects of the methylation levels
remained for several loci. Despite the fact that banding is not likely
to inﬂuence the results due to the longitudinal nature of the
analysis, we further investigated the potential impact. For that
purpose we used the ‘gaphunter’ function from the minﬁ
package17 to identify possible banding of the DNA methylation
levels at the DMPs and DMRs. Distinct bands of methylation levels
were identiﬁed in 12 of the 17 DMPs and in 5 of the 12 DMRs (see
Tables 2A and 2B). The proportion of CpG sites showing banding
was much higher in the DMPs than expected by chance
(χ2 = 1 299 628, df = 3, P-valueo2.2e-16). As the bands were
suggestive of genetic effects in cis or trans, previously published
mQTL data sets were explored and all bands could be connected
with mQTLs, thus suggesting that genetic effects underlie the
banding in distribution of DNA methylation levels. Next, the
inﬂuences of the bands per locus on the results of longitudinal
analyses were investigated using multilevel analysis using the
bands as random factor in a mixed effect model. The identiﬁed
bands did not inﬂuence the observed associations between
longitudinal changes in PTSD symptoms and changes in DNA
methylation for 16 out of the 17 DMPs and at 10 out of the 12
DMRs. Multilevel analysis however rendered the associations for
Figure 2. Boxplot of the results of pathway analyses. Pathways containing more than the expected number of genes with PTSD-associated
changes in DNA methylation levels. The data were imported into PathVisio, corrected for the number of probes per gene and
overrepresentation analysis of the WikiPathways curated for analysis pathway collection was performed using a signiﬁcant Šídák-adjusted P-
value of o0.05 and a change in the methylation estimate of at least 0.01 as criteria. Z-scores of signiﬁcant pathways (Z-score41.96) are
displayed. Full tables of the pathway overrepresentation analysis results are provided in Supplementary Tables S4 and S5. PTSD, post-
traumatic stress disorder.
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the DMP cg04657146 in HOOK2, the DMR in HOOK2 and the DMR
in SMAD5 (see Tables 2A and 2B) nonsigniﬁcant. Stratiﬁed analyses
per band for these loci showed that the signiﬁcant associations
were retained only for distinct bands in the DMP at cg04657146 in
HOOK2 and in the DMRs in HOOK2 and SMAD5. Thus, these results
suggest interplay between genetic background and DNA methy-
lation changes in the development of PTSD, particularly for
these loci.
DNA methylation marks and traumatic stress
Inclusion of a deployed but unexposed control group in this
prospective study enabled us to separately investigate associa-
tions between the severity of traumatic stress exposure during
deployment and longitudinal changes in DNA methylation in
subjects who did not develop PTSD symptoms after deployment
(i.e. resilient individuals). These analyses were performed in
individuals who showed no signiﬁcant changes in PTSD symptom
scores over time but reported either low or high levels of
traumatic stress (see Table 1B). The analyses were constrained to
CpG sites in the 17 DMPs and 12 DMRs exhibiting a signiﬁcant
genome-wide association with changes in PTSD symptoms. The
results indicated that exposure to traumatic stress in these
individuals was associated with longitudinal increases (rather than
decreases) in DNA methylation at the DMPs and DMRs (see
Figure 2). In contrast to the negative associations between PTSD
symptoms and DMPs and DMRs observed in the trauma-exposed
groups (see Figure 2 and, for the network between the DMRs,
Figure 2a), trauma exposure was positively associated with
changes in DNA methylation levels at these DMPs and DMRs in
military subjects who did not show increases in PTSD symptoms
but were differentially exposed to traumatic stress (see Figure 2b).
In other words, whereas trauma exposure increased DNA
methylation levels at the DMPs and DMRs over time in the group
that did not develop PTSD symptoms, the group that developed
PTSD symptoms after trauma exposure showed decreased DNA
methylation at the identiﬁed DMPs and DMRs (see also
Supplementary Figure S3 which exempliﬁes the results on the
DMRs in ZFP57 and RNF39). These results reveal opposite effects in
susceptibility and resilience to the effects of traumatic stress
exposure, which are thus related to directionally differential DNA
methylation responses, at least for the investigated DMPs
and DMRs.
The results of the bioinformatics analyses of gene ontology and
pathway enrichment as well as network analyses are described in
the Supplementary Tables S1 and S2, Supplementary Figure S4
and summarized in Figure 3. The analyses identiﬁed signiﬁcant
enrichment in a range of pathways (see Figure 2 and
Supplementary Tables S1 and S2) including several pathways with
clear relevance for brain functioning and stress-related disorders,
such as ‘Sudden Infant Death Syndrome (SIDS) Susceptibility
Pathways’, ‘Circadian rhythm related genes’, ‘Wnt Signaling Path-
way and Pluripotency’, ‘Dopaminergic neurogenesis’, ‘Neural Crest
Differentiation’, ‘IL17 signaling pathway’, ‘TSH signaling pathway’,
‘Serotonin Receptor 2 and ELK-SRF/GATA4 signaling’, and ‘Seroto-
nin Transporter Activity’.
Replication of DMRs and DMPs related to PTSD susceptibility
The 17 DMPs and 12 DMRs that were identiﬁed in the discovery
data set were tested in the replication data set using the same
regression analysis of longitudinal changes in DNA methylation, in
which longitudinal changes in PTSD symptom scores were the
main determinant of longitudinal changes in DNA methylation. In
addition, the data were adjusted for three ancestry-related
principal components to deal with ethnic diversity in this
sample.18 Replication was obtained for two DMRs and one DMP
at which longitudinal changes in PTSD symptom scores were
Figure 3. Network of genetically annotated regions showing differential DNA methylation. Networks of genes in differentially methylated
regions (DMRs) and their direct interaction partners. Genes in/near DMRs (Table 2B) were uploaded into GeneMania. Interaction partners of
several types were added, using the default settings, extending the network with 20 additional nodes (interaction partners). Three genes were
not connected (PM20D1, WASF3, ZFP57). The resulting network was imported into Cytoscape. The data were mapped to the network,
visualizing the estimated methylation changes associated with increased PTSD symptom scores in subjects exposed to traumatic stress (a)
and with exposure to trauma in subjects without increased PTSD symptom scores (b) using a colour gradient. The border size represents the
P-value: the Šídák-adjusted P-value for the DMR for genes in DMRs (both panels) and, for others, the most signiﬁcant individual Šídák-adjusted
P-value for all associated CpGs according to GREAT annotation (a). Genes with a transcriptional start site near the DMRs are displayed as
rounded boxes, and partners added by GeneMania are displayed as ellipses. Edges are visualized according to the GeneMania colour scheme.
The data for the X-chromosomal XIAP were not available in the data set. Two DMRs were located near the transcription start site of DUSP22,
and the most signiﬁcant P-value for these two is shown. PTSD, post-traumatic stress disorder.
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signiﬁcantly associated (with the same directionality) with
changes in DNA methylation (see also Table 2A). The two repli-
cated DMRs were the DMR in ZFP57 at chromosome six between
positions 29 648 161 and 29 649 025 (near the transcription start
site of ZFP57; P= 1.32E-14) and the DMR in RNF39 between
positions 30 039 374 and 30 039 601 (near the transcriptional start
site of RNF39 and PPP1R11; P= 0.0026) at chromosome six. The
replicated DMP was located in HIST1H2APS2 (cg03517284 B=
− 0.15, P= 0.002). Although these showed the same direction of
effect in the replication data as in the discovery, we also observed
that the DMPs located in DUSP22 (cg03395511 B= 0.44, P= 0.005;
cg18110333 B= 0.59, P= 0.016; cg21548813 B= 0.38, P= 0.028;
cg01516881 B= 0.21, P= 0.027) and SDK1 (cg07249765 B= 0.50,
P= 0.017) showed a similar statistical association between
changes in DNA methylation and changes in PTSD status in the
replication data, but with opposite directionality as in the
discovery data set (see also Table 2A). Therefore, DUSP22 and
SDK1 methylation changes were considered to be non-
replications. A limitation of the replication was that the distribu-
tion of the baseline and follow-up samples across arrays and
positions was different and differences between batch correction
procedures may have inﬂuenced the robustness of replications
attempt. Sensitivity analyses adjusting for changes in the cell-type
distribution did not alter the signiﬁcance of replicated ﬁndings.
Technical validation
The robustness of the array-based DNA methylation data was
validated by pyrosequencing the same CpG sites of DMRs in ZFP57
and RNF39 in the discovery data set. High correlations were
observed between pyrosequencing-based DNA methylation
results and the array-based results for the average DNA
methylation level of the loci in the ZFP57 DMR (correlation = 0.96,
Po0.001) and for the average DNA methylation level of the loci in
the RNF39 DMR (correlation = 0.95, Po0.001) (see also
Supplementary Figure S5). The associations between longitudinal
alterations in PTSD symptom scores and longitudinal alterations in
the average DNA methylation level remained statistically sig-
niﬁcant for the DMR in ZFP57 (B=− 2.49, P= 0.021) when using
pyrosequencing-based data, although this was not observed for
the pyrosequencing-based data for the average DNA methylation
levels of the DMR in RNF39 (B=− 1.12, P= 0.36).
Associations with broader expression of psychopathology
Longitudinal changes in scores on the SCL-90 questionnaire in the
discovery data set were signiﬁcantly associated with longitudinal
changes in DNA methylation levels in the DMP in HIST1H2APS2
(cg03517284 B=− 0.05, P= 0.033) and the DMR in ZFP57
(B=− 0.06, P= 0.008) but not with the DMR in RNF39 (B=− 0.03,
P= 0.346). The main results on associations with the DMRs in
ZFP57 and RNF39 and the DMP in HIST1H2APS2 are summarized
in Table 3.
DISCUSSION
This is the ﬁrst hypothesis-free study of longitudinal changes in
blood DNA methylation proﬁles across the period of exposure to
combat trauma in relation to the development of PTSD. Genome-
wide discovery with targeted replication of within-subject
alterations in DNA methylation revealed that decreasing DNA
methylation levels at the genes ZFP57, RNF39 and HIST1H2APS2 (all
located on chromosome six) were related to the increasing levels
of PTSD symptoms over time. Bioinformatics analyses of the
identiﬁed genes also indicated signiﬁcant enrichment for the
neuronal compartment in important brain-related biological
pathways.
A major strength of the present study is the prospective
sampling and phenotype assessments conducted before and after
a period of deployment in subgroups enriched for trauma
exposure and PTSD outcomes for genome-wide discovery with
targeted replication in a second military prospective military
cohort. The main ﬁndings were technically validated using
bisulphite pyrosequencing, and although the analytical sensitivity
of bisulﬁte pyrosequencing is ~ 5–10% for individual CpG sites
and, thus, does not have the sensitivity necessary to detect small
(i.e. o5%) changes in DNA methylation,19 we still observed
evidence for the robustness of associations when using the
pyrosequencing-based data. The longitudinal design of our study
furthermore reduced the likelihood of confounding, including
confounding by the genetic variants eliminating both cis and trans
effects of the genotype on DNA methylation, as has previously
been observed.20–22
The strongest evidence was found for two DMRs, one in ZFP57
and one in RNF39. Susceptibility to PTSD and broader expression
of psychopathology were associated with hypomethylation at
ZFP57 in two independent samples, and by using two techniques
Table 3. Overview of main results
Data set and
analysis
GENE nearby probes ZFP57 RNF39 HIST1H2APS2
DMR of cg20228636,
cg27414868, cg11383134 and
cg03198009
DMR of cg09279736,
cg13401893, cg12633154,
cg10568066 and cg16078649
DMP at cg03517284
Methylome
analyses in
discovery data set
Association of methylation change
with development of PTSD
symptoms
+ + +
Targeted analyses
in replication data
set
Association of methylation change
with development of PTSD
symptoms
+ + +
Targeted analysis in
discovery data set
Statistical mediation of change in
PTSD symptoms by methylation
− + −
Targeted analysis in
discovery data set
Association of methylation change
with development of general
psychopathology symptoms
+ − +
Abbreviations: DMP, differentially methylated point; DMR, differentially methylated region; PTSD, post-traumatic stress disorder; SCL-90, Symptom
Check List—90-item questionnaire. A statistically signiﬁcant result is indicated by ‘+’, while ‘ –‘ indicates that the result was not statistically signiﬁcant.
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for measuring DNA methylation levels. ZFP57 encodes zinc-ﬁnger
protein 57, which functions as a transcriptional regulator of
genomic imprinting in stem cells during development and in adult
life.23,24 ZFP57-dependent genomic imprinting requires the
co-factor KAP1, and a recent rodent study has observed that
conditional knock-out of KAP1 in the hippocampus induces
behavioural susceptibility to stress, and is associated with
epigenetic marks on a distinct set of genes in the
hippocampus.25 Thus, together, these data are consistent with a
key role for ZFP57-KAP1 genomic imprinting in susceptibility to
traumatic stress. This role in imprinting raises the question of
whether this locus is involved in transgenerational inheritance of
disease vulnerability.
The second DMR was located in RNF39. We discovered and
replicated associations between susceptibility to develop PTSD
upon traumatic stress exposure and hypomethylation in the
RNF39 DMR in the blood. DNA methylation at RNF39 signiﬁcantly
mediated the associations between traumatic stress exposure and
changes in PTSD symptoms. These ﬁndings suggest that RNF39 is
a key gene regulator of stress susceptibility in humans, a ﬁnding in
line with results from genome-wide association studies showing
that common variants in RNF39 increase the risk of
schizophrenia,26 anger27 and risk of major psychiatric
disorders.28 RNF39 encodes ring ﬁnger protein 39, which plays a
role in the early phase of synaptic plasticity and in long-term
potentiation.29 A recent micro-array study has shown that rodents
previously exposed to stress show elevated RNF39 mRNA
expression in the hippocampal dentate gyrus in response to
corticosterone challenge, as compared with animals not exposed
to prior stress.30 Another animal stress study has shown that
RNF39 mRNA levels are also strongly upregulated in the lateral
amygdala during Pavlovian fear conditioning.31 Together, these
ﬁndings support the role of RNF39 in mediating the effect of stress
on central fear and stress circuitries in the brain and on stress-
related behaviour.
It is noteworthy that replication of the DMRs was more
successful compared with that of the DMPs. Two DMRs and only
one DMP showed consistent effects across data sets, and can thus
be considered as candidate regions for susceptibility to trauma-
related disorder. It also suggests a superior biological meaning of
DMRs and lower rate of false positives for such regions as
compared with single CpG loci.
The analysis of longitudinal DNA methylation changes in the
discovery data set indicated opposite directions of the relationship
with trauma compared with PTSD symptom levels in all genome-
wide signiﬁcant DMPs and DMRs. This divergence in the general
response to trauma and the development of symptoms is
consistent with a maladaptive response to trauma in those who
develop PTSD and raises the question of whether the differential
psychological and behavioural responses to traumatic stress may
be traced to the epigenomic level. The mechanisms underlying
these epigenetic changes remain to be established but may
include inter-individual differences in one-carbon metabolism,
including folate levels or a number of other regulators of
transcription.
The bioinformatic pathway analyses of the discovery data set
further showed strong links between the development of
symptoms of PTSD and DNA methylation in distinct biological
pathways with relevance for neuronal functioning and with prior
evidence for mediation of stress susceptibility and in PTSD. These
pathways comprised the dopaminergic and serotonergic
neurotransmission,32,33 WNT signalling pathway and β-catenin;34
the hypothalamus–pituitary–adrenal axis, including CRF
signalling;4,35 circadian rhythm, complement activation, the
immune system including IL-17 signalling; and the brain-derived
neurotrophic factor and neurotrophin signalling pathways.
The results of this study should be interpreted in the context of
several limitations. Further studies of the identiﬁed loci and genes
are needed to establish the biological relevance in the brain in
relation to trauma and trauma-related mental disorders. The
limitations include the relatively small sample size and the use of a
male, mainly Caucasian population, thus precluding generalization
of our ﬁndings to females, other trauma types and other
populations. Indeed, the limited replication also suggests that
differences between studies (and study designs) are large, and
many confounders may be at play including, for example, diet and
immune status. In addition to population-speciﬁc properties, the
observed DNA methylation changes were small, that is, lower than
5%, which may have inﬂuenced the technical validation of array-
based and pyrosequencing-based DNA methylation analyse
(particularly for loci with low DNA methylation level, e.g., the
RNF39 DMR). Thus, initiatives to converge epigenetic studies
using DNA samples collected in large cohorts of patients with
PTSD and trauma-exposed controls,36 employed with similar
epidemiological designs and analysed simultaneously in the same
or parallel batches of arrays, are warranted in order to reduce
false-positive ﬁndings and optimize the power of these discovery
endeavours.
Overall, this study is effective in highlighting those loci that
have strong and consistent association with disease risk.
Identiﬁcation of these loci thereby provides new leads for the
understanding of the mechanisms of differential responses to
traumatic stress and for how epigenetic alterations may play a role
in the development of PTSD.
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